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Ambulatory blood pressure monitoring in older people with dementia:  a 
systematic review of tolerability 
Abstract n = 255 
Background: Ambulatory Blood Pressure Monitoring (ABPM) may be helpful for the 
management of hypertension, but little is known about its tolerability in people with 
dementia.  
Objective: to review the published evidence to determine the tolerability of ABPM in 
people with dementia. 
Methods: English language search conducted in MEDLINE and EMBASE, using 
‘Ambulatory blood pressure’ AND ‘Dementia’ (and associated synonyms) from 1996-
March 2015. Inclusion criteria: people diagnosed with dementia AND in whom blood 
pressure was measured using ABPM. The initial search was undertaken using title and 
abstract reviews, with selected papers being agreed for inclusion by two reviewers. 
Potentially eligible papers were assessed, and high quality papers retained. Two 
reviewers agreed the abstracted data for analysis. Meta-analysis was used to combine 
results across studies. 
Results: Of the 221 screened abstracts, 13 studies (6%) met inclusion criteria, five had 
sufficient data and were of sufficient quality, involving 461 participants, most of whom 
had mild-moderate dementia. 
77.7% (95% CI 62.2-93.2%)were able to tolerate ABPM; agreement with office BP was 
moderate to weak (two studies only - coefficients 0.3-0.38 for systolic blood pressure 
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and 0.11-0.32 for diastolic blood pressure). One study compared home BP monitoring by 
a relative or ambulatory BP monitoring with office BP measures, and found high 
agreement (κ 0.81). The little available evidence suggested increased levels of dementia 
being associated with reduced tolerability. 
Conclusions: ABPM is well-tolerated in people with mild-moderate dementia, and 
provides some additional information over and above office BP alone. However, few 
studies have addressed ABPM in people with more severe dementia. 
Key words 
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 Ambulatory blood pressure monitoring 
Key points 
 Essential hypertension and dementia commonly co-exist 
 People with dementia are particularly susceptible to the potential harms 
associated with over-treatment of hypertension 
 Ambulatory Blood Pressure Monitoring is a useful adjunct to office blood 
pressure monitoring, and is tolerated in people with dementia able to attend 
clinics 
 There is a paucity of data on the tolerability of blood pressure monitoring in 
people with more advanced dementia 
 
Background 
Hypertension is a global health challenge, with a prevalence of 50% in community 
dwelling people aged 65 years or older [1]. Out-of-office Blood Pressure (BP) is an 
important adjunct to conventional office or clinic measurement, which presently remains 
an important method for screening, diagnosing and managing hypertension [2]. Out-of-
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office BP monitoring includes 24-hour Ambulatory Blood Pressure Monitoring (ABPM), as 
well as home blood pressure monitoring (HBPM); both have the advantage of capturing a 
number of BP measurements in a more natural environment [2]. ABPM is therefore 
particularly useful in patients with anxiety, or potential haemodynamic side effects such 
as symptomatic hypotension, or where BP variability is expected or observed. The 2011 
National Institute for Health and Clinical Excellence (NICE) guidelines suggested that the 
diagnosis and treatment decisions in hypertension should no longer be based on office 
measurements alone, and that confirmatory out-of-office measurements should be 
mandatory [1]. 
Dementia represents another global health challenge, affecting 35.6 million people 
worldwide in 2010 [3]. The prevalence of hypertension in people with dementia ranges 
between 35%-84% [4]. ABPM is likely to be particularly useful in the management of 
hypertension in people with dementia, who commonly experience issues such as anxiety, 
haemodynamic side-effects and BP variability. However, for ABPM to be useful in 
widespread practice in people with dementia, it needs be tolerable and acceptable, and 
produce results that are complementary to office measures.  
The most recent European guidelines do not advise on the management of hypertension 
in older people with dementia [2]. It appears that little is known about the tolerability of 
ABPM in people with dementia, so we undertook a review of the existing literature. 
The aim of this systematic review was to determine the tolerability of home BP 
monitoring in older people with hypertension and dementia, defined as follows: 
• Tolerability of using 24 hour ambulatory BP measurement in people with 
dementia  
• The correlation between ABPM and office blood pressure measurements 
Methods 
An English language search of Medline and EMBASE databases (1996+) was conducted 
in December 2013 and updated in March 2015; the search terms were: 
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• dementia.mp. OR exp Dementia, Vascular/ OR exp Dementia, Multi-
Infarct/ OR exp Dementia/ 
AND 
• ambulatory blood pressure.mp. OR exp Blood Pressure Monitoring, 
Ambulatory/ OR 24 hour blood pressure.mp. 
A hand search of the references of extracted articles was also conducted to identify 
potential studies not captured in the electronic database searches. 
Inclusion criteria 
• Studies including people diagnosed with dementia 
• BP was measured using HBPM or ABPM  
One team member (MK) screened abstracts identified from the initial search. If a study 
met the initial selection criteria or its eligibility could not be determined from the title or 
abstract, the full text was retrieved. Two reviewers (MK and SC) then independently 
assessed the full text papers for inclusion eligibility; any discrepancies were resolved 
through discussion. 
Included studies were graded using the Critical Appraisal Skills Programme (CASP) tool 
for observational studies by both reviewers [5]. A cut-off score of more than 50% for 
scored items was used for retaining papers, with disagreements again resolved through 
discussion. 
Outcomes 
The primary outcome of interest was the proportion of individuals with dementia who 
were able to tolerate ABPM (as defined according to the individual study criteria, or if not 
stated, then using the definition of tolerability from O’Brien et al [2003][6] which 
requires a minimum of 14 readings during the day and seven readings at night). 
Secondary outcomes included: 
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• Agreement between ABPM readings versus clinic BP in people with 
dementia 
• Any reasons why ABPM was not tolerated in people with dementia 
Data were extracted from the selected papers using a spreadsheet by both reviewers 
independently, and where this was not available, the original authors were contacted for 
further information. Considerable efforts were made to track down primary data 
including web searches to identify authors that had changed institution and personal 
contacts with co-authors or collaborators; if the authors were not contactable or the data 
not available, the study was excluded. 
The PRISMA statement [7] was used to guide design and reporting. 
Analysis 
Data were abstracted from the original papers by two reviewers (MK, SC), and cross-
checked for accuracy. 
The proportion of people able to tolerate 24-hour ABPM was combined in a meta-
analysis. Heterogeneity was quantified with the I2 statistic, which measures the 
percentage of variation among studies due to heterogeneity rather than to chance. We 
considered heterogeneity to be important when I2 was more than 30%. As it was 
deemed appropriate to combine studies, if there was high heterogeneity, a random 
effects model was used. The meta-analysis was undertaken using MedCalc Statistical 
Software version 15.2.2 (MedCalc Software, Ostend, Belgium; http://www.medcalc.org; 
2015). 
A similar approach was used for the correlation coefficients (and accompanying standard 
deviations); Cohen’s interpretation was used (0.10-0.29 - weak relationship, 0.30-0.49 - 
medium relationship, ≥0.50 - strong relationship [8]). 
Any descriptive data on the tolerability of ABPM was to be synthesised using a thematic 
analysis. 
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This work was undertaken during MK’s academic clinical fellowship, there was no specific 
funding. 
Results 
221 abstracts were identified from the initial search of which 10 (5%) met the inclusion 
criteria (see Figures 1 and 2) [Nesti 2014 [9], Plichart 2013 [10], Chen 2013 [11], Kim 
2012 [12], Mossello 2012 [13], Kennelly 2011 [14], Zulli 2008 [15], Yamamoto 2002 
[16], Yamamoto 2005 [17] and Puisieux 2001 [18]]. Two of the papers referred to the 
same cohort of patients assessed at different time points, so both were considered 
potentially eligible [Yamamoto 2002 & 2005]. 
At least some outcome data were available for five papers [Nesti 2014 [9], Plichart 2013 
[10], Kennelly 2011 [14], Mossello 2012 [13] and Zulli 2008 [15]]; for remaining five 
papers, the data were missing or unobtainable. The five papers with missing data for our 
primary outcome were broadly similar to the included studies, and in total looked at 268 
older people with vascular or Alzheimer’s dementia in a clinic setting. 
Of the studies for which there was data, four were cohort studies [Nesti 2014, Plichart 
2013, Mossello 2012, Kennelly 2011] and one was a case-control study [Zulli 2008]; all 
scored more than 50% on the CASP scores. The studies reported upon 461 participants, 
with mean ages ranging from 69 to 81 years, and most patients included in the studies 
had mild to moderate dementia, with a Mini-Mental State Examination (MMSE) score 
ranging from 9 to 23. All reported upon ABPM, with no studies reporting upon home BP 
monitoring. The overall quality of studies was good (mean CASP score 79%). The study 
selection process in shown in figure 1 and the summary data are shown in table 1.
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Figure 1 Flow diagram of selection of studies focusing on ambulatory blood 
pressure measurement in people with dementia
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Records excluded not 
meeting inclusion 
criteria 
(n = 197) 
Records screened 
(n = 24, see Figure 2) 
Full-text articles assessed for 
eligibility (n = 10) 
Full-text articles not obtained because:  
(i) conference proceedings only (n=5) 
(ii) authors not contactable to 
determine eligibility (n = 5) 
(iii) duplicate publications (n=4) 
Studies included for analysis 
(n = 5, see Table 1) 
Full-text articles 
excluded because of 
missing key 
outcomes n=5 
4 studies included in final tolerability 
meta-analysis 
(n=4, see Table 1) 
(n = 5, see Table 1) 
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Table 1 Summary of the main study characteristics 
References  Population Study design & CASP 
score 
Measurement Primary outcome   
 
Proportion able to 
tolerate 24-hour 
monitoring 
Secondary outcomes 
 
Correlation between 
ABPM and office (cuff) 
 
 
Assessment of 
tolerability of ABPM  
 
Nesti 2014 176 people with dementia 
(DSM-IV criteria) or MCI 
attending memory clinics 
 
Mean MMSE 21.7, range 
10-27 
 
Mean age 79 
 
Italy 
Cohort 
 
CASP score 91% 
24-hour ABPM 
monitoring 
using 
SpaceLabs 
Medical 90207 
device 
 
Tolerability 
defined as at 
least 54 
readings over 
24-hours 
147/176 (84%) 
tolerated for 24 
hours 
 
45 of the 147 did not 
achieve the defined 
minimum for this 
study (mean for 
those not tolerating 
49 (SD 5) readings) 
 
Overall tolerability 
rate using the 
criteria for this study 
= 102/176 (58%)  
Not stated Failure rates higher in 
those with MMSE score in 
the lower tertile (29%) vs 
upper tertile (7%) 
 
Failure rates higher in 
those with higher 
Neuropsychiatric Inventory 
Indexes (e.g. 30% vs 8%) 
Plichart 
2013 
60 patients with dementia 
(criteria not stated) 
 
Mean MMSE 20.1 (SD 6.9) 
 
Mean age 80.8 
 
France 
Cohort, randomly 
allocated to sequential 
home BP monitoring by a 
relative OR 24-hour 
ABPM 
 
CASP score 82% 
 
24-hour ABPM 
monitoring 
using Novacor 
DIASYS 200 
device 
 
12/18 
readings for 
relative home 
BP monitoring 
 
54/60 (90%) Reported as agreement 
for diagnosis of 
hypertension with office 
BP – κ 0.81, 95% CI, 
0.61–0.93, “strong”. 
No assessment of 
tolerability/acceptability 
Mossello 
2012 
 
100 patients in a nursing 
home 
 
No. of patients with AD not 
defined, but mean MMSE in 
survivors 16.5, and 8.6 in 
those that died during 
follow-up 
 
Cohort 
 
CASP score 68% 
24-hour ABPM 
monitoring 
using Space 
Labs Medical 
90207 device 
 
Number of 
readings for 
inclusion of 
Not given Systolic = 0.30, p=0.025  
“weak” 
 
Diastolic = 0.11, p>0.05 
“weak” 
No assessment of 
tolerability/acceptability 
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Mean age survivors: 82, 
died during follow-up 85 
 
Italy 
ABPM results 
in the analysis 
not defined. 
Kennelly 
2011 
Diagnoses of probable AD 
according to NINCDS-
ADRDA Alzheimer’s criteria 
 
Group A (no treatment) 
n=30  
Mean age: 71.2 
MMSE: 22.6 
 
Group B (treatment) 
n=56 
Mean age: 69.3 
MMSE: 21.5 
 
Ireland 
 
Cohort 
 
CASP score 80% 
24-hour ABPM 
monitoring 
using A&D TM-
2430 device 
 
Number of 
readings for 
inclusion of 
ABPM results 
in the analysis 
not defined. 
68/86 (79%) Systolic = 0.38 
“moderate” 
 
Diastolic = 0.32 
“moderate” 
No assessment of 
tolerability/acceptability 
Zulli 2008 39 patients with 
Alzheimer’s dementia (DSM 
IV and NINCDS-ADRDA 
criteria) 
 
Male/Female, n: 13/20  
Age, mean (SD): 72.1  (SD 
8.2) 
Mean MMSE 19.0 (SD 4.3) 
 
Italy 
Case control (data for 39 
with dementia reported 
only) 
 
CASP score 73% 
24-hour ABPM 
monitoring 
using 
SpaceLabs 
Medical 90207 
device  
 
Number of 
readings for 
inclusion of 
ABPM results 
in the analysis 
not defined. 
33/39 (85%) Not stated No assessment of 
tolerability/acceptability 
Note: subject characteristics are for people with dementia within a given cohort conducted in the respective studies unless indicated otherwise, SBP: systolic blood 
pressure, DBP: diastolic blood pressure, NINCDS-ADRDA: National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's disease and 
Related Disorders Association, DSM: Diagnostic and Statistical Manual of Mental Disorders. 
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For the primary outcome (the proportion of individuals with dementia who were able to 
tolerate ABPM), I2 was 91% indicating significant heterogeneity, therefore the random 
effects estimate was used for the summary estimate. In a population with predominantly 
mild-moderate and some with severe dementia, ABPM tolerability was 77.7% (95% CI 
62.2-93.2%) (Figure 2). 
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Figure 2 Reported 24-hour ABPM tolerability for people with dementia 
 
 
Only two studies reported agreement between office BP and home BP measurements 
(Kennelly, Mosselo); Pearson’s correlation coefficients were moderate-weak for both 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 91.5%, p = 0.000)
Zulli 2008
Study
Nesti 2014
ID
Plichart 2013
Kenelly 2011
0.78 (0.62, 0.93)
0.85 (0.69, 0.94)
0.58 (0.50, 0.65)
ES (95% CI)
0.90 (0.79, 0.96)
0.79 (0.69, 0.87)
100.00
23.46
%
25.87
Weight
25.50
25.17
  
0-.962 .962
NOTE: Weights are from random effects analysis
Overall  (I-squared = 91.4%, p = 0.000)
Plichart 2013 (n=60)
Kenelly 2011 (n=86)
Nesti 2014 (n=176)
Zulli 2008 (n=39)
ID
Study
0.78 (0.62, 0.93)
0.90 (0.79, 0.96)
0.79 (0.69, 0.87)
0.58 (0.50, 0.65)
0.85 (0.69, 0.94)
ES (95% CI)
  
0-.96 .96
Page 12 
 
systolic and diastolic blood pressure (0.30-0.38 and 0.11-0.32 respectively). Plichart 
reported a kappa coefficient comparing home BP monitoring by a relative to ambulatory 
BP monitoring, which was strong (0.81). Given the paucity of data on correlation or 
agreement, a meta-analysis was not undertaken. 
Only one study (Nesti 2014) examined further the issues underpinning tolerability, 
noting that people with more severe dementia or higher levels of agitation measured 
using the Neuropsychiatric Index were less tolerant of ambulatory BP monitoring. 
Discussion  
The overall tolerability of ABPM monitoring in people with dementia was 77.7% (95% CI 
62.2-93.2%) based on our meta-analysis of four studies, which is similar to other patient 
cohorts [19, 20]. The correlation between ABPM and office BP measurements was 
moderate to weak, but based on only two studies. Little was reported on the reasons 
why ABPM was not tolerated, but more advanced dementia appears to be associated 
with less tolerability. People with more severe cognitive impairment were significantly 
under-represented in these studies; most of the studies only included populations that 
were well enough to attend clinic settings, including the five excluded studies for who 
our primary outcome was not available.  
The studies included were heterogeneous in terms of design (cohort studies and case 
control studies), but similar in that they reported on blood pressure measurement in 
people with dementia; the overall quality was high (minimum CASP score 68%). Despite 
efforts to contact authors of original studies to identify all possible data, we were unable 
to obtain data from studies involving older people with moderate to severe dementia. 
The studies that were identified but not included in this review appeared similar in terms 
of the population studied, but it is possible that ABPM might be in use in those with 
moderate to severe dementia and only a limited amount of this experience has been 
studied and reported. This limits the generalisability of the findings to populations with 
more severe cognitive impairment.  
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The correlation between ABPM and office BP measurements was moderate to weak, in 
contrast to studies involving people without dementia, which find strong correlations of 
around 0.61 for systolic BP and 0.55 for diastolic BP [21]. Although this could be 
interpreted as demonstrating that ABPM is potentially inaccurate, a more likely 
interpretation is that there are important differences in ambulatory and clinic BP 
measures in people with dementia and hence that ABPM offers complementary 
information. However there were only two studies reporting on this and further studies 
would be required before making any clinical recommendations based on these data. 
These findings provide some reassurance that, in a predominantly clinic-based 
population with dementia, ABPM will be feasible in the majority. This is helpful as older 
patients with cognitive dysfunction are at increased risk of white coat hypertension [22], 
and so might be used to avoid unnecessary treatment in those people who do not have 
sustained hypertension. Additional advantages of ABPM include identification of periods 
of hypotension, which is associated with a range of adverse outcomes in people with 
dementia, including accelerated cognitive decline [23-26] and falls [27]. ABPM can also 
identify orthostatic hypotension, which accompanies hypertension in around 30% of 
older people in general [28], which is associated with vascular mortality [29] and all-
cause mortality [30]. 
This review has not fully addressed the issue of assessing blood pressure in people with 
more advance dementia, who were under-represented in the studies to date, and 
arguably who are at greater risk of harm. 
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